Lurbinectedin as monotherapy was found to show an improvement in objective response rate in patients with relapsed small cell lung cancer, meeting the primary endpoint of a phase II trial by both investigator review and an independent review committee.
Original Article: Lurbinectedin Monotherapy Improves ORR in Relapsed SCLC